Literature DB >> 19596110

Antibiotic resistance: the perfect storm.

I M Gould1.   

Abstract

The worldwide epidemic of antibiotic resistance is in danger of ending the golden age of antibiotic therapy. Resistance impacts on all areas of medicine, and is making successful empirical therapy much more difficult to achieve. Antibiotic choices are often severely restricted, and the pipeline of new antibiotics is almost dry. Resistance cannot be prevented, but its development and spread can be slowed. One of the tools at our disposal is maximising diversity in our prescribing. The advent of tigecycline, the first in a new class of intravenous antibiotics, is important in this context, giving us a further monotherapy option for severe infections. Another strategy is seriously to curtail the large amount of unnecessary antibiotic use in many areas of life, not only medical practice. The various aspects of this strategy are briefly reviewed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19596110     DOI: 10.1016/S0924-8579(09)70549-7

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  36 in total

1.  Increased carriage of macrolide-resistant fecal E. coli following mass distribution of azithromycin for trachoma control.

Authors:  Jessica C Seidman; Christian L Coles; Ellen K Silbergeld; Joshua Levens; Harran Mkocha; Lashaunda B Johnson; Beatriz Muñoz; Sheila K West
Journal:  Int J Epidemiol       Date:  2014-03-21       Impact factor: 7.196

Review 2.  Advancing Diagnostics to Address Antibacterial Resistance: The Diagnostics and Devices Committee of the Antibacterial Resistance Leadership Group.

Authors:  Ephraim L Tsalik; Elizabeth Petzold; Barry N Kreiswirth; Robert A Bonomo; Ritu Banerjee; Ebbing Lautenbach; Scott R Evans; Kimberly E Hanson; Jeffrey D Klausner; Robin Patel
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

3.  Bioengineered lysozyme in combination therapies for Pseudomonas aeruginosa lung infections.

Authors:  Karl E Griswold; Jenna L Bement; Charlotte C Teneback; Thomas C Scanlon; Matthew J Wargo; Laurie W Leclair
Journal:  Bioengineered       Date:  2014-02-26       Impact factor: 3.269

Review 4.  Methodology in improving antibiotic implementation policies.

Authors:  Onur Özgenç
Journal:  World J Methodol       Date:  2016-06-26

5.  Structural optimization and antibacterial evaluation of rhodomyrtosone B analogues against MRSA strains.

Authors:  Liyun Zhao; Hongxin Liu; Luqiong Huo; Miaomiao Wang; Bao Yang; Weimin Zhang; Zhifang Xu; Haibo Tan; Sheng-Xiang Qiu
Journal:  Medchemcomm       Date:  2018-09-07       Impact factor: 3.597

6.  Community-acquired pneumonia: impact of empirical antibiotic therapy without respiratory fluoroquinolones nor third-generation cephalosporins.

Authors:  J Pradelli; K Risso; F G de Salvador; E Cua; R Ruimy; P-M Roger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-10-02       Impact factor: 3.267

7.  Specific N-terminal cleavage of ribosomal protein L27 in Staphylococcus aureus and related bacteria.

Authors:  Erin A Wall; J Harry Caufield; Charles E Lyons; Keith A Manning; Terje Dokland; Gail E Christie
Journal:  Mol Microbiol       Date:  2014-12-08       Impact factor: 3.501

8.  A novel approach to the antimicrobial activity of maggot debridement therapy.

Authors:  Anders S Andersen; Dorthe Sandvang; Kirk M Schnorr; Thomas Kruse; Søren Neve; Bo Joergensen; Tonny Karlsmark; Karen A Krogfelt
Journal:  J Antimicrob Chemother       Date:  2010-06-11       Impact factor: 5.790

9.  Sphingosine kinase-1 is required for toll mediated beta-defensin 2 induction in human oral keratinocytes.

Authors:  Manjunatha R Benakanakere; Jiawei Zhao; Johnah C Galicia; Michael Martin; Denis F Kinane
Journal:  PLoS One       Date:  2010-07-09       Impact factor: 3.240

10.  Host gene expression classifiers diagnose acute respiratory illness etiology.

Authors:  Ephraim L Tsalik; Ricardo Henao; Marshall Nichols; Thomas Burke; Emily R Ko; Micah T McClain; Lori L Hudson; Anna Mazur; Debra H Freeman; Tim Veldman; Raymond J Langley; Eugenia B Quackenbush; Seth W Glickman; Charles B Cairns; Anja K Jaehne; Emanuel P Rivers; Ronny M Otero; Aimee K Zaas; Stephen F Kingsmore; Joseph Lucas; Vance G Fowler; Lawrence Carin; Geoffrey S Ginsburg; Christopher W Woods
Journal:  Sci Transl Med       Date:  2016-01-20       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.